Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and... see more

TSXV:VPT - Post Discussion

View:
Post by jpinkman on May 04, 2021 9:29am

NEWS/INFO

Dear Friend;
 
Attached is a news release announcing the Company has been awarded an IRAP grant for $120,000 to continue development of the VMS+.  Here is some background:
 
1.    We have had IRAP grants before to develop version 3 (VMS+3.0) and also to explore conventional machine-learning AI to automate point selection, which works and is being integrated into a future VMS+ product.  IRAP grants are quite prestigious as they are hard to get and so having multiple grants shows how our innovative team is viewed by the experts, who review the applications. Our track history of success is also a big plus in these applications.
2.    A few weeks ago we announced the filing of a patent for novel 4D (motion) measurements of heart function.  This IRAP grant is to advance this project.  The goal here is to “own” these novel measurements of heart function.  We have been working with a advisory group of elite cardiologists to develop these measurements and we will soon be ready to try them out on archival echocardiograms to begin to understand how they would inform cardiologist about the best way to treat various heart conditions - exciting stuff.
3.    The project also allow us to add routine 2D measurements into the VMS+ family of products (2D, 3D and 4D) to make it more convenient for users.  We already have this function in the GE Healthcare version and want to add it to the standalone version as well.
4.    We are focused on selling the VMS+3.0, but for all products, it is important to keep advancing them and to be responsive to your customer’s suggestions for improvements.  This grant will give us the extra resources to accomplish this next upgrade.
 
Thank you for your continued interest and support as we continue our mission to improve cardiac diagnostics for everyone worldwide and especially for children.
Comment by leonenoel on May 04, 2021 9:34am
where did you get this? is it a separate news release?
Comment by Pandora on May 04, 2021 10:32am
Toronto, Ontario – TheNewswire – May 4, 2021 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is excited to announce that it is receiving advisory services and research and development funding of up to $120,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to further enhance ...more  
Comment by leonenoel on May 04, 2021 10:43am
Thanks. I should clarify that I was interested in the letter explaining the news release.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities